Evofem Biosciences Story

Requested story not found. it has been either deleted or moved. View all stories for Evofem Biosciences.

Evofem Biosciences Latest Timeline

Evofem Biosciences is listed for 0.05. Evofem Biosciences currently holds about 19.89 M in cash with (146.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.